Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785913 · ClinicalTrials.gov registry record · Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02785913 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 31 participants.
The verdict
NCT02785913, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the phosphoinositide 3-kinase (PI3K) biomarker. PI3K can cause tumor cells to grow more quickly. Taselisib may decrease the activity of PI3K and may be able to shrink tumors.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Taselisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02785913
The ClinicalTrials.gov registry entry for NCT02785913 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02785913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02785913 about?
NCT02785913 is a clinical study titled "Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches". This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the phosphoinositide 3-kinase (PI3K) biomarker. PI3K can caus...
What is the current status of trial NCT02785913?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-11. Estimated completion is 2019-11.
What interventions are being tested in trial NCT02785913?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Taselisib (DRUG).
Who is sponsoring clinical trial NCT02785913?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.